$VNDA

AI Analysis

Generated on May 12, 2026

AI Score
55/ 100
Hold$VNDA

Vanda Pharmaceuticals Inc.

$VNDANASDAQHealthcareSmall-Cap

Vanda Pharmaceuticals develops and commercializes therapies for central nervous system disorders. Key products include Hetlioz for non-24-hour sleep-wake disorder and Fanapt for schizophrenia.

Market Cap
$350.0M
Revenue (TTM)
$250.0M
-5.0%
Net Income (TTM)
$25.0M
-15.0%
EPS (TTM)
$0.45
P/E Ratio
14.0
Dividend Yield
0.0%
52-Week Range
$4.50-$8.00
Beta
0.65
Dimension Scores
Fundamental
58
Technical
48
Sentiment
52
Risk / Reward
60
Momentum
45
FundTechSentRiskMome
Financial Health
Profitability
63moderate
Growth
48weak
Liquidity
68strong
Solvency
60moderate
Efficiency
56moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $VNDA

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.